The evaluation and management of testosterone deficiency: The new frontier in urology and men's health

Current Urology Reports

Volumn 14, Issue 6, 2013, Pages 557-564

  Conners III, William P ^a   Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgens; Erectile dysfunction; Libido; Male sexual dysfunction; Metabolic syndrome; Prostate cancer; Sexual dysfunction; Testosterone

Indexed keywords

ANASTROZOLE; ANDROGEN; ANDROSTANOLONE; AROMATASE INHIBITOR; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; GONADORELIN; GONADORELIN AGONIST; KETOCONAZOLE; LUTEINIZING HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ACNE; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; AZOOSPERMIA; BLOOD ANALYSIS; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG FATALITY; DRUG FORMULATION; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; ERYTHROCYTOSIS; FOOT EDEMA; GYNECOMASTIA; HORMONE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOGONADISM; KIDNEY FAILURE; LIBIDO DISORDER; LIVER TOXICITY; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORGASM DISORDER; PATHOPHYSIOLOGY; PATIENT MONITORING; PHYSICAL EXAMINATION; PREVALENCE; PROSTATE CANCER; RISK FACTOR; SEXUAL DYSFUNCTION; SLEEP DISORDERED BREATHING; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL;

ERECTILE DYSFUNCTION; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; OBESITY; OSTEOPOROSIS; TESTOSTERONE;

EID: 84887196404     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0370-5     Document Type: Article

References (59)

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States 2001-2011. JAMA Intern Med epub Jun 3, 2013.
2. Mulligan T et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-9. (Pubitemid 43881152)
3. Wu FC et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-35.
4. • Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2356-59. An excellent reference for the field, and one of the most widely cited. It is important to note that the authors acknowledge promoting a conservative approach to treatment.
5. th ed 1997 403-33.
6. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179(4):1235-42.
7. Bremner W et al. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278-81. (Pubitemid 13055125)
8. Crawford E et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int. 2007;100(3):509-13. (Pubitemid 47205476)
9. Harman S et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study on Aging. J Clin Endocrinol Metab. 2001;86(2):724-31. (Pubitemid 32207487)
10. •• Wu et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737-45. An invaluable dataset showing what happens with aging to testosterone, free testosterone, SHBG, and LH, and how obesity and other factors influence testosterone. (Pubitemid 352008544)
11. Gray A et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-25. (Pubitemid 21901140)
12. • Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124(7):578-87. A more liberal approach to the field of testosterone deficiency and its treatment, taking into consideration the evidence regarding the general health benefits of testosterone therapy in men who are testosterone-deficient.
13. Laaksonen D et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036-41. (Pubitemid 38579762)
14. Oh J et al. Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care. 2002;25(1):55-60. (Pubitemid 41070783)
15. Yeap B et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health in Men Study. Eur J Endocrinol. 2009;161(4):591-8.
16. Pitteloud N et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90(5):2636-41. (Pubitemid 40686302)
17. Malkin C et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313-8. (Pubitemid 38951897)
18. Akishita M et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30(11):1029-34.
19. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-92. (Pubitemid 38133769)
20. Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2356-59.
21. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7(4 Pt 2):1627-56.
22. Morgentaler A. Commentary: Guideline for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab. 2007;92:416-7.
23. Vermeulen A et al. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-72. (Pubitemid 30645223)
24. Moreno S, Shyam A, Morgentaler A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. J Sex Med. 2010;7:1948-53.
25. Reyes-Vallejo L et al. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. J Sex Med. 2007;4:1757-62. (Pubitemid 47616869)
26. Rhoden E et al. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol. 2003;170(3):795-8. (Pubitemid 36999558)
27. Hwang T et al. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006;18:400-4.
28. • Di Sante S et al. Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy. J Sex Med. 2012;9(2):585-93. Study showing that in routine clinical practice testosterone therapy in T-deficient men significantly increases lean mass (muscle) and decreases fat mass after mean 6 mo of treatment.
29. Snyder P et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647-53. (Pubitemid 30641987)
30. Amory et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503-10. (Pubitemid 38269849)
31. Corona G et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(2):337-53.
32. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726-33.
33. • Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013. First long-term study (5y) of testosterone therapy, provocatively showing substantial and progressive weight loss and reduced waist circumference in obese and overweight men with low testosterone concentrations.
34. Westaby D et al. Liver damage from long-term methyltestosterone. Lancet. 1977;2:262-3.
35. Swerdloff R et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-10. (Pubitemid 32157624)
36. Conners W, Flinn K, Morgentaler A. Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy. J Sex Med. 2011;8(12):3465-70.
37. McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion. J Sex Med. 2012;9(2):594-601.
38. Wang et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89(8):3821-9. (Pubitemid 39071479)
39. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab. 1995;80(12):3546-52.
40. Crews D, Morgentaler A. Effects of intracranial implantation of oestradiol and dihydrotestosterone on the sexual behavior of the lizard Anolis carolinensis. J Endocrinol. 1979;82:373.
41. Anderson RA, Wallace AM, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J Clin Endocrinol Metab. 1996;81(3):902-8. (Pubitemid 26083944)
42. Hanafy H. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med. 2007;4(5):1241-6. (Pubitemid 47337667)
43. Ruige J et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97(11):870-5.
44. Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol. 2009;51:303-13.
45. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68-75.
46. Khaw K-T et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694-701. (Pubitemid 350291241)
47. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-22.
48. Morgentaler A. Words of wisdom. Re: Adverse events associated with testosterone administration. Eur Urol. 2011;59:465.
49. Huggins C, Hodges C. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.
50. Morgentaler A. Testosterone and Prostate Cancer: An historical perspective on a modern myth. Eur Urology. 2006;50:935-9. (Pubitemid 44486489)
51. Roddam AW et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. JNCI. 2008;100:170-83. (Pubitemid 351480553)
52. Muller RL, Gerber L, Moreira DM, et al. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012;62:757-64.
53. Calof O et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontology. 2005;60(11):1451-7. (Pubitemid 41798454)
54. Morgentaler A. Turning Conventional Wisdom Upside-Down: Low Serum Testosterone and High-Risk Prostate Cancer. Cancer. 2011;117:3885-8.
55. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536-41. (Pubitemid 46190961)
56. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639-44.
57. Morgentaler A, Lipshultz LI, Avila Jr D, Bennett R, Sweeney M, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185:1256-61.
58. •• Morgentaler A, Traish A. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310-20. This article produced a new way of understanding the relationship between androgens and prostate cancer. It explained why androgen deprivation causes dramatic decreases in PSA but testosterone therapy produces little if any increase in PSA in most men.
59. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology. 2006;68:1263-7. (Pubitemid 44880344)